Genetic testing company InVitae said last week that its 211-gene sequencing-based assay that screens for just over 260 genetic conditions is now being offered to early-access customers.

In a presentation at Cambridge Healthtech Institute's Clinical Genome Conference in San Francisco last week, CEO Randy Scott said that the company is working with 20 to 30 early-access physicians.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.